期刊文献+

Functional and metabolic complications of androgen deprivation therapy

Functional and metabolic complications of androgen deprivation therapy
下载PDF
导出
摘要 Prostate cancer is the most common non-cutaneous cancer in men worldwide.Several different treatment strategies are available including minimally invasive procedures for localized tumors such as radical prostatectomy,radiotherapy,and androgen deprivation therapy,among others.All these strategies can be given as mono-therapy or as combination therapy.For this review,we will focus on the side effects of androgen deprivation therapy,independent of the other treatment modalities.Some of the most common affections are loss of bone mineral density,weight gain and obesity,myocardial infarction and sudden death,metabolic syndrome and insulin resistance,dyslipidemia,loss of libido and erectile dysfunction,fatigue,cognitive decline,vasomotor flushing,to mention a few.All these alterations can have an impact on quality of life and even lead to more serious complications such as fractures and cardiovascular complications.We present recommendations for prevention,early recognition and treatment.The different modalities for androgen deprivation therapy have particular side-effects profiles and indications should be made in an individualized manner.Androgen deprivation therapy is a useful tool for some patients with prostate cancer but every effort should be made to avoid related complications.The use of guidelines and educational programs for both,patients and urologists,are extremely useful strategies. Prostate cancer is the most common non-cutaneous cancer in men worldwide.Several different treatment strategies are available including minimally invasive procedures for localized tumors such as radical prostatectomy,radiotherapy,and androgen deprivation therapy,among others.All these strategies can be given as mono-therapy or as combination therapy.For this review,we will focus on the side effects of androgen deprivation therapy,independent of the other treatment modalities.Some of the most common affections are loss of bone mineral density,weight gain and obesity,myocardial infarction and sudden death,metabolic syndrome and insulin resistance,dyslipidemia,loss of libido and erectile dysfunction,fatigue,cognitive decline,vasomotor flushing,to mention a few.All these alterations can have an impact on quality of life and even lead to more serious complications such as fractures and cardiovascular complications.We present recommendations for prevention,early recognition and treatment.The different modalities for androgen deprivation therapy have particular side-effects profiles and indications should be made in an individualized manner.Androgen deprivation therapy is a useful tool for some patients with prostate cancer but every effort should be made to avoid related complications.The use of guidelines and educational programs for both,patients and urologists,are extremely useful strategies.
机构地区 Department of Urology
出处 《World Journal of Clinical Urology》 2014年第3期227-237,共11页 世界临床泌尿杂志
关键词 PROSTATE cancer Metabolic SYNDROME FRAILTY SYNDROME COMPLICATIONS Sarcopeny ANDROGEN DEPRIVATION therapy Prostate cancer Metabolic syndrome Frailty syndrome Complications Sarcopeny Androgen deprivation therapy
  • 相关文献

参考文献2

二级参考文献68

  • 1Huggins C, Hodges C. Studies on prosate cancer. Effect of castration, estrogen, and adrogen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
  • 2Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining "hot flashes" in men. Urol Nurs 1994; 14: 155-8.
  • 3Loprinzi CL, Sherry L. Hot flushes: mostly sex neutral? Lancet Oncol2010; 11: 1074.
  • 4Kading P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170-3.
  • 5Shanafet TD, BaRon DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207-18.
  • 6Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003: 101: 337-45.
  • 7Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S et al. A phase III randomized, double-bli nd, placebo-controlled trial of gabapentin in the management of hot flashes in men (NOOCB). Ann Oncol2009; 20: 542-9.
  • 8Pa ndya K J, Morrow GR, Roscoe JA, Zhao H, Hickok JT et al Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366: 818-24.
  • 9Reddy SY, Warner H, Guttuso T Jr, Messing S, Digrazio W et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8.
  • 10Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK etal. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347-52.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部